![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: INSL5 |
Gene summary for INSL5 |
![]() |
Gene information | Species | Human | Gene symbol | INSL5 | Gene ID | 10022 |
Gene name | insulin like 5 | |
Gene Alias | PRO182 | |
Cytomap | 1p31.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9Y5Q6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10022 | INSL5 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.78e-05 | 2.28e+00 | -0.2602 |
10022 | INSL5 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.90e-02 | 2.76e+00 | -0.2196 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSL5 | SNV | Missense_Mutation | c.76G>T | p.Val26Leu | p.V26L | Q9Y5Q6 | protein_coding | tolerated(0.76) | benign(0.005) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
INSL5 | SNV | Missense_Mutation | c.178N>C | p.Glu60Gln | p.E60Q | Q9Y5Q6 | protein_coding | deleterious(0.04) | probably_damaging(0.958) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
INSL5 | SNV | Missense_Mutation | c.230N>C | p.Asn77Thr | p.N77T | Q9Y5Q6 | protein_coding | tolerated(1) | benign(0.007) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
INSL5 | SNV | Missense_Mutation | novel | c.371A>G | p.Asp124Gly | p.D124G | Q9Y5Q6 | protein_coding | tolerated(0.32) | benign(0.018) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSL5 | SNV | Missense_Mutation | rs770529302 | c.47C>T | p.Ala16Val | p.A16V | Q9Y5Q6 | protein_coding | deleterious(0.03) | possibly_damaging(0.568) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSL5 | SNV | Missense_Mutation | rs765987055 | c.104N>A | p.Arg35Gln | p.R35Q | Q9Y5Q6 | protein_coding | deleterious(0.01) | probably_damaging(0.935) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
INSL5 | SNV | Missense_Mutation | rs140992561 | c.212G>A | p.Arg71His | p.R71H | Q9Y5Q6 | protein_coding | tolerated(1) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSL5 | SNV | Missense_Mutation | c.346N>A | p.Asp116Asn | p.D116N | Q9Y5Q6 | protein_coding | deleterious(0.04) | benign(0.277) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
INSL5 | SNV | Missense_Mutation | c.57N>C | p.Glu19Asp | p.E19D | Q9Y5Q6 | protein_coding | tolerated(0.1) | possibly_damaging(0.907) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
INSL5 | SNV | Missense_Mutation | c.110N>C | p.Val37Ala | p.V37A | Q9Y5Q6 | protein_coding | tolerated(0.08) | possibly_damaging(0.841) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |